Results 51 to 60 of about 17,797 (277)

Fecal incontinence: the quality of reported randomized, controlled trials in the last ten years. [PDF]

open access: yes, 2008
This study was designed to analyze the characteristics and the quality of reporting of randomized, controlled trials published during the last ten years on fecal ...
Chelvanayagam, Sonya   +2 more
core   +1 more source

Pregabalin: a range of misuse-related unanswered questions [PDF]

open access: yes, 2019
© 2019 The Authors.
Chiappini, Stephania, Schifano, Fabrizio
core   +2 more sources

Left Ventricular Regional Wall Motion Abnormality in the Setting of Acute Loperamide Overdose

open access: yesClinical Practice and Cases in Emergency Medicine, 2019
Loperamide is an inexpensive, over-the-counter antidiarrheal agent with emerging reports of overdose due to its opioid properties. Although it is considered by many patients to be safe, cardiotoxicity has been reported, prompting the United States Food ...
Kasha Bornstein   +2 more
doaj   +1 more source

Loperamide-Induced Acute Pancreatitis [PDF]

open access: yesCase Reports in Gastrointestinal Medicine, 2013
Acute pancreatitis is a common disease leading to hospitalizations, most often caused by gallstones or alcohol. We present a case of a patient diagnosed with acute pancreatitis considered to be due to loperamide treatment for diarrhea.
Halla Vidarsdottir   +3 more
openaire   +3 more sources

Evaluation of the antidiarrhoeal and antidiabetic activities of the leaf aqueous extract of Syzygium cordatum hoscht. ex C.Krauss (Mytraceae) in rodents [PDF]

open access: yes, 2013
Syzygium cordatum Hoscht. ex C.Krauss is widely used by traditional medicine practitioners to treat many ailments including diarrhoea and diabetes.
Amabeoku, G.J., Deliwe, M.
core   +1 more source

Risk of Cardiac Lesion with Chronic and Acute Use of Loperamide—An Integrative Review

open access: yesJournal of Cardiovascular Development and Disease, 2022
Loperamide is a synthetic opioid commonly used as an antidiarrheal due to its activation of u-opioid receptors in the myenteric plexus. In therapeutic doses, it inhibits peristalsis and has anti-secretory and anti-motility effects, until metabolized by ...
Bruna Cremonezi Lammoglia   +9 more
doaj   +1 more source

Glycogenic Hepatopathy: A Case Report of a Rare Complication in Uncontrolled Diabetes. [PDF]

open access: yesClin Case Rep
ABSTRACT Glycogenic hepatopathy (GH) is an underrecognized yet reversible cause of hepatomegaly and transaminase elevation in adolescents with poorly controlled type 1 diabetes mellitus (T1DM). While liver biopsy is often utilized to exclude other hepatic pathologies, it can also aid in confirming GH when noninvasive findings are inconclusive.
Musleh M, AlMokbel A.
europepmc   +2 more sources

Loperamide Mimicking Brugada Pattern [PDF]

open access: yesMethodist DeBakey Cardiovascular Journal, 2018
Brugada syndrome is an inherited arrhythmia that increases a patient's risk of sudden cardiac death. Certain pharmacologic agents may induce a transient Brugada pattern on surface electrocardiogram (EKG). One of these is loperamide, an over-the-counter agent commonly used to manage diarrhea.
Hilda Mariana Gonzalez Bonilla   +6 more
openaire   +3 more sources

Sojae Semen Praeparatum Fermented by Rhizopus chinensis and Bacillus sp. DU‐106 Alleviates Loperamide‐Induced Constipation in Rats via Regulating Calcium Signaling Pathways and the Gut Microbiota

open access: yesFood Frontiers, EarlyView.
To investigate the effects of different processing methods of Sojae Semen Praeparartum (SSP) on constipation, we prepared SSP through fermentation using Rhizopus chinensis and Bacillus sp. DU‐106 as starter cultures, and examined its laxative effects and mechanisms in loperamide‐induced constipated Sprague‐Dawley (SD) rats.
Rong xiang Guo   +9 more
wiley   +1 more source

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract The neurokinin 3 receptor antagonist fezolinetant is an approved treatment for vasomotor symptoms due to menopause. The impacts of hepatic and renal impairment on the pharmacokinetics and safety of a single oral dose of fezolinetant 30 mg were investigated in two independent studies.
Megumi Iwai   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy